Login to Your Account

Afraxis, Genentech Sign PAKt; Up to $187M for 'Novel Target'

By Randy Osborne
Staff Writer

Tuesday, January 29, 2013
Less than a month after BioMarin Pharmaceutical Inc. acquired Zacharon Pharmaceuticals Inc. for $10 million up front plus potential milestone payments, Avalon Ventures has scored another win in Afraxis Inc.'s potential $187.5 million licensing deal with Genentech, a member of the Roche Group.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription